Alcon acquires Neurotech for $550 million, adds approved retinal treatment
Key Facts
Alcon acquired Neurotech Pharmaceuticals for $550 million, with potential additional payments tied to commercial milestones, according to Investing.com, citing the statement on the deal announced on 20 October. The acquired company owns Encelto, which Neurotech described as the "first and only treatment approved by the U.S. Food and Drug Administration" for macular telangiectasia. The FDA-approved indication covers adults with idiopathic macular telangiectasia type 2. Alcon thus adds to its portfolio a treatment that has already secured regulatory approval and moved into manufacturing, shipping and commercial use, according to Neurotech's announcements. The potential additional consideration is tied to commercial milestones for the business, alongside the announced acquisition price.
The treatment targets a disease whose progression, Neurotech said, is accompanied by blurred and distorted vision and difficulty reading, ultimately leading to loss of central vision. Encelto is administered through surgical implantation inside the eye, according to the FDA's description of its use. Implantation requires a single surgical procedure performed by a qualified ophthalmologist, according to the agency. The treatment works by producing recombinant human ciliary neurotrophic factor, which may support the survival of macular photoreceptors. This therapeutic approach links production of the factor inside the eye to support for photoreceptor survival, according to the mechanism outlined by the FDA in its discussion of the treatment. The approved use remains limited to adult patients with this type of disease.
U.S. approval of Encelto dates to 5 March 2025, according to the approval letter published by the FDA. The primary assessment of its efficacy was based on 2 Phase 3 trials, which the agency said were identical in design. The agency described the trials as adequate and well-controlled, comparing the treatment with a sham surgical procedure. Following regulatory approval, Neurotech announced the start of commercial manufacturing and shipping of the treatment, as well as its commercial surgical procedure. Its announcement covered these stages together, from product manufacturing through delivery and surgical use, as part of its transition to commercial use. Alcon's acquisition therefore follows completion of this regulatory process and the start of actual treatment delivery, according to the sequence outlined in Neurotech's announcements.
In its commercial update issued in March 2026, Neurotech reported that enrollment in the treatment's patient support portal had exceeded 700 patients. It said Encelto implant procedures had surpassed 100 surgeries, including treatment of the second eye where appropriate. On insurance, the company announced the adoption of 88 medical coverage policies representing about 200 million insured people. Its update brought together enrollment in the patient support program, completed treatment procedures and the expansion of insurance coverage for the product. It also said it had existing commercial manufacturing capacity designed to meet current and future demand for the treatment. These developments illustrate the stages of commercial activity included in the deal, from patient support and medical coverage to manufacturing and implant procedures.
Alcon enters the deal after reporting sales of about $2.8 billion in the second quarter of 2026, according to its financial results announcement. Sales rose 8% on a reported basis from the corresponding period, the company said. Alcon previously acquired a majority stake in Aurion Biotech, which it described as a clinical-stage company developing advanced cell therapies for eye diseases. In a separate capital allocation development, Alcon announced the termination of its agreement to acquire STAAR Surgical. David Endicott said when announcing the termination of that agreement: "Throughout this process, we maintained our discipline in assessing price and risk." Neurotech fits into this context of Alcon's ophthalmic treatment deals, with an approved product already in commercial use.
As for the acquisition's expected financial impact, Alcon expects the deal to be modestly accretive to net sales growth, according to Investing.com, citing its statement. On earnings, the company expects slight dilution to core diluted earnings per share in 2027 because of the deal. It then expects the acquisition to become accretive to earnings thereafter, according to the forecasts reported by the website. Alcon's estimates for the coming period thus combine a modest contribution to net sales growth with a slight negative impact on earnings per share in the specified year. This estimate places the shift to earnings accretion in the period after 2027, according to the company's expected trajectory for the acquisition.